{
    "clinical_study": {
        "@rank": "119146", 
        "arm_group": [
            {
                "arm_group_label": "Evening Only (full-dose)", 
                "arm_group_type": "Active Comparator", 
                "description": "The dosing regimen of Crystalline lactulose will be four 45-gram doses (one dose every 60 minutes for 4 straight hours) taken the evening before the colonoscopy procedure."
            }, 
            {
                "arm_group_label": "Split-dose", 
                "arm_group_type": "Experimental", 
                "description": "The dosing regimen of Crystalline lactulose will be three 45-gram doses (one dose every 60 minutes for 3 straight hours) taken the evening before the colonoscopy procedure followed by one 45-gram dose the morning before the colonoscopy procedure."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the efficacy of a split-dose regimen of\n      crystalline lactulose for cleansing of the colon as a preparation for colonoscopy, as\n      assessed by the physician's determination of the cleanliness of the colon using the Boston\n      Bowel Prep Scale (BBPS)."
        }, 
        "brief_title": "Safety, Efficacy, and Patient Preference of Split-Dose Crystalline Lactulose as a Preparation for Colonoscopy in Adults", 
        "completion_date": {
            "#text": "September 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Colonoscopy", 
        "detailed_description": {
            "textblock": "This is a single center, open-label, pilot study to determine the safety, efficacy, and\n      patient preference of a split-dose regimen of Crystalline Lactulose for cleansing of the\n      colon prior to colonoscopy. Safety will be assessed by the occurrence of any treatment\n      emergent adverse events. Efficacy will be determined by the endoscopist's rating of the\n      cleanliness of the colon and the incidence of treatment failure (insufficient evacuation of\n      the bowel). Patient preference will be determined by the patient's responses on a patient\n      questionnaire."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients requiring bowel evacuation for colonoscopy\n\n        Exclusion Criteria:\n\n          -  Patients with galactosemia (galactose-sensitive diet)\n\n          -  Patients known to be hypersensitive to any of the components of Crystalline Lactulose\n\n          -  Patients with a history of a failed bowel preparation\n\n          -  Patients with severe constipation, defined as those patients taking daily\n             prescription or over-the-counter laxatives\n\n          -  Patients with possible bowel obstruction, previous colonic surgery, gastric\n             retention, bowel perforation, toxic colitis, toxic megacolon, or ileus\n\n          -  Patients on lactulose therapy or receiving any treatment for chronic constipation\n\n          -  Patients less than 18 years of age\n\n          -  Inability to understand the requirements of the study or be unwilling to provide\n             written informed consent (as evidenced by signature on an informed consent document\n             approved by an Institutional Review Board [IRB]) and agree to abide by the study\n             restrictions\n\n          -  Be pregnant or nursing\n\n          -  Be otherwise unsuitable for the study, in the opinion of the Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01650870", 
            "org_study_id": "SplitDose Cryst. Lactulose"
        }, 
        "intervention": {
            "arm_group_label": [
                "Evening Only (full-dose)", 
                "Split-dose"
            ], 
            "intervention_name": "Crystalline Lactulose", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gastrointestinal Agents", 
                "Lactulose"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Cathartics", 
            "Laxatives", 
            "Lactulose", 
            "Gastrointestinal Agents", 
            "Therapeutic Uses", 
            "Pharmacologic Actions"
        ], 
        "lastchanged_date": "July 24, 2012", 
        "location": {
            "contact": {
                "last_name": "Jody Mooney, MSAOM", 
                "phone": "206-341-1452"
            }, 
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98101"
                }, 
                "name": "Virginia Mason Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Center, Randomized, Single-blind Pilot Study to Determine the Safety, Efficacy, and Patient Preference of Split-Dose Regimen of Crystalline Lactulose for Cleansing of the Colon as a Preparation for Colonoscopy in Adults", 
        "overall_contact": {
            "last_name": "Jody Mooney, MSAOM", 
            "phone": "206-341-1452"
        }, 
        "overall_official": {
            "affiliation": "Virginia Mason Medical Center", 
            "last_name": "Otto Lin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the primary objective of efficacy of the split-dose, the following endpoint will be measured:\no Physician's determination of the cleanliness of the colon will be evaluated by completion of the Boston bowel prep scale.", 
            "measure": "Cleanliness of the Colon During Colonoscopy", 
            "safety_issue": "No", 
            "time_frame": "Day of the procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01650870"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the secondary objective of efficacy, the following endpoint will be measured:\no The number and percentage of patient's who by the physician's determination are considered treatment failures (patients with insufficient evacuation of the bowel=Boston bowel prep score < 5, and/or any colon segment score of 0).", 
                "measure": "Treatment Failures", 
                "safety_issue": "No", 
                "time_frame": "Day of the procedure"
            }, 
            {
                "description": "To evaluate the secondary objective of patient tolerability and preference on the basis of the following assessments: Patient tolerability and preference questionnaire including 100 mm Visual Analog Scale (VAS) and Likert Scale", 
                "measure": "Patient Tolerability and Preference", 
                "safety_issue": "No", 
                "time_frame": "Day before and day of colonoscopy"
            }, 
            {
                "description": "To evaluate the secondary objective of measuring colonic hydrogen and methane gas production as measured by:\no Colonic hydrogen and methane gas levels.", 
                "measure": "Colonic Hydrogen and Methane Gas Production", 
                "safety_issue": "No", 
                "time_frame": "Day of colonoscopy"
            }, 
            {
                "description": "To evaluate the secondary objective of safety as measured by the incidence of treatment emergent adverse events", 
                "measure": "Safety/Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Day before colonoscopy till 7 days after colonoscopy"
            }
        ], 
        "source": "Benaroya Research Institute", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Virginia Mason Hospital/Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Cumberland Pharmaceuticals", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Benaroya Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}